VOLUNTARY ANNOUNCEMENT - LATEST RESEARCH RESULTS ON TQ-A3334 “TLR7 AGONIST” AND BEPIROVIRSEN “ASO” TO BE PRESENTED AT 2026 AASLD

NEXT DAY DISCLOSURE RETURN

NEXT DAY DISCLOSURE RETURN

VOLUNTARY ANNOUNCEMENT - COMPLETION OF ALL SUBJECTS ENROLMENT IN THE PHASE III REGISTRATIONAL CLINICAL TRIAL OF TQC3721 INHALATION SUSPENSION “PDE3/4 INHIBITOR”

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 SEPTEMBER 2026

VOLUNTARY ANNOUNCEMENT - ENTER INTO STRATEGIC BIOSIMILARS PARTNERSHIP WITH STADA

2026 INTERIM REPORT

NOTIFICATION LETTER AND REPLY FORM FOR REGISTERED SHAREHOLDERS